Weekly Recap | INSILICO -0.47%, most brokers rate it buy

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

INSILICO (3696.HK) slipped 0.47% this week to close at HK$37.82, while the Hang Seng Index fell 3.32%, leaving the stock outperforming by roughly 2.85 percentage points. The stock made an early push then pulled back: it opened Monday (9 November) at HK$39.50, touched a high of HK$41.36 on Wednesday (11 November), then slid to HK$37.00 on Thursday (12 November) before settling at HK$37.82. The weekly range was 11.04%, with average daily volume around 8.4 million shares, 33.6% below the median.

Key Events

The main corporate development arrived on Friday (13 November): Insilico Medicine announced a strategic AI-powered drug discovery partnership with Luoxin Pharmaceuticals, focused on innovative treatments for digestive, metabolic and other chronic diseases. The collaboration was disclosed via a voluntary announcement and was the only in-week news item. Under the agreement, the subsidiary will apply AI-driven discovery capabilities to chronic disease pipelines. The stock had already reached its weekly high of HK$41.36 on Wednesday before easing back, coinciding with the announcement timing.

Analyst Ratings

A total of 11 brokers cover the stock: 8 rate it buy and 3 rate it overweight, with no hold, underweight or sell ratings. The consensus rating is strong buy, with a consensus target price of HK$77.89, about 105.9% above the latest price of HK$37.82. Target prices range from HK$50.003 to HK$100.013, a wide band reflecting divergent views on valuation. Within the life science tools and services industry, the stock ranks 6th out of 12 companies by analyst rating.

The Week Ahead

Hong Kong macro data is in focus next week: the unemployment rate is due on Tuesday (17 November), with a prior reading of 3.9%, followed by the composite consumer price index on Friday (20 November), with a prior reading of 1.9%. On the company side, the Luoxin Pharmaceuticals collaboration is still at the strategic framework stage; any follow-up on milestones or pipeline progress would be worth monitoring.

In Short

The ratings picture is warm: all 11 brokers rate the stock buy or overweight, and the consensus target price sits more than double the current share price. Yet the stock did not follow that consensus higher this week—it pulled back after the early run, and the latest trading day showed net selling by large-lot money. Valuation-wise, the stock trades at 5.18x PB, near the lower end of the 60-day range between HK$37.00 and HK$41.36. The key question ahead is whether the partnership translates into pipeline progress, and how Hong Kong macro data feeds into sentiment toward biotech names.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.